Glioma stem cells (GSCs) are glioblastoma (GBM) cells that are resistant to therapy and can give rise to recurrent tumors. The identification of patient-related factors that support GSCs is thus necessary to design effective therapies for GBM patients. Glucocorticoids (GCs) are used to treat GBM-associated edema. However, glucocorticoids participate in the physiological response to psychosocial stress, which has been linked to poor cancer prognosis. This raises concern that glucocorticoids affect the tumor and GSCs. Here, we treated primary human GBM cells with dexamethasone and evaluated GC-driven changes in cell morphology, proliferation, migration, gene expression, secretory activity and growth as neurospheres. Dexamethasone treatment of GBM cells appeared to promote the development of a GSC-like phenotype and conferred resistance to physiological stress and chemotherapy. We also analyzed a potential correlation between GC treatment and tumor recurrence after surgical excision in a population-based consecutive cohort of 48 GBM patients, adjusted for differences in known prognostic factors concerning baseline and treatment characteristics. In this cohort, we found a negative correlation between GC intake and progression-free survival, regardless of the MGMT methylation status. In conclusion, our findings raise concern that treatment of GBM with GCs may compromise the efficacy of chemotherapy and may support a GSC population, which could contribute to tumor recurrence and the poor prognosis of the disease.
Glioblastoma multiforme (GBM) is an aggressive malignant primary brain tumor with a poor prognosis. Patients survive around 15 months after diagnosis despite standard surgical resection, chemotherapy and radiotherapy. 1 Because of their infiltrative nature, GBM cells cannot be completely excised. Radiotherapy and chemotherapy are designed to target rapidly dividing cancer cells and often fail to target a population known as glioma stem cells (GSCs). GSCs share certain phenotypic and functional characteristics with neural stem cells. When implanted in low numbers in animal models, they can grow as new or recurrent tumors similar to the primary tumor.
of CD133 between the cell surface (isolated as CD133-positive) and the cytoplasm (isolated as CD133-negative). 4 These observations highlight the potential plasticity of GBM cells, which may cycle between GSCs and more differentiated phenotypes, leading to incongruent research results. The identification of patient-related factors capable of reprogramming GBM cells into GSCs is thus of paramount importance for developing effective treatments.
Most GBM patients receive high doses of glucocorticoids (GCs) at the time of diagnosis and before and after surgical resection of the tumor. Endogenously produced by the adrenal cortex, these steroid hormones exert their cellular and physiological effects by binding to GC receptors, which are expressed in a vast variety of cells throughout the body. GCs released into the circulation easily diffuse through cellular membranes and bind to GC receptors in the cytoplasm, altering their conformation and enabling them to translocate into the nucleus to activate or repress gene transcription. Alternatively, GCs trigger signaling by binding to GC receptors in the cytoplasm or the cell membrane. Through these means, GCs play a central role in the physiological response to stress and regulate development, homeostasis, metabolism and immune response. 7 Synthetic GCs with longer bioavailability and stronger affinity for the GC receptor are widely prescribed as antiinflammatory and immunosuppressive agents. 8 They are also used to treat hematological malignancies, as they appear to induce apoptosis of malignant cells through poorly understood mechanisms. 9 In the treatment of solid tumors, GCs are used as adjuvants to decrease the side effects of chemotherapy and radiotherapy and to alleviate metastasis-related pain. 9 In malignant brain tumors, GCs are a first line of care to decrease tumor-associated brain inflammation and edema. 10 However, the specific effect of GCs on cancer cells from solid tumors is largely disregarded in the clinic and remains only a topic of debate in experimental studies. 11 Psychosocial stress, which increases endogenous GC levels, appears to influence the appearance of malignant brain tumors and correlates with poor prognosis in cancer patients. 12 Moreover, previous studies indicate that GCs can have a profound impact on the gene expression profile of astrocytes and regulate the expression of astrocyte-derived growth factors that are implicated in the proliferation of neural precursor cells. 13, 14 In this study, we assessed the effects of dexamethasone, a synthetic GC routinely prescribed to patients, on GBM cells.
We also assessed a potential correlation between tumor recurrence and treatment with GCs in a population-based cohort of consecutive GBM patients treated at the Karolinska University Hospital. We find evidence of a concerning potential effect of GCs on tumor progression, likely linked to GCmediated enhanced stemness in glioblastoma cells.
Material and Methods

Isolation and culture of primary GBM cells
Samples of surgically resected human primary GBMs were obtained from the Karolinska University Hospital, Sweden, shortly after surgery. The samples were reduced to a singlecell suspension by mechanical dissociation and treatment with Accutase (Sigma-Aldrich), and expanded through in vitro culture and frozen for later use. GBM primary cells were then cultured in differentiation cell culture medium or in stem cell culture medium. The differentiation medium was composed of DMEM/F12, 10% fetal bovine serum, 100 U/ml penicillin and 100 lg/ml streptomycin. The stem cell culture medium was composed of DMEM/F12, 20 ng/ml epidermal growth factor, 20 ng/ml basic fibroblast growth factor, 1 3 B27, 100 U/ml penicillin and 100 lg/ml streptomycin. When specified 10 27 or 10 26 M dexamethasone was added to either medium. In this study, cells were isolated from the following tumors: GBM30, GBM42 and GBM48. GBM30 tumor was positive for GFAP, negative for p53 mutation, had high degree of atypia and mitosis with an MIB index of 80% and with signs of low degree of differentiation. GBM42 tumor was positive for GFAP, negative for p53 mutation, had a high degree of atypia and mitosis with an MIB index of 35%. GBM48 was positive for GFAP, positive for p53 mutation, an MIB index of 25%, no 1p or 19q deletions, but with an olygodendrocyte component.
Cell proliferation
One thousand cells per well were plated on 96-well plates. Fresh cell culture medium was added every 3-4 days. At various times after plating, enzymatic activity in live cells was measured with the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega Biotech) according to the manufacturer's instructions.
Migration assay
Cell migration was assessed with the scratch assay. Cells were cultured for 2 weeks in the presence or absence of
What's new?
Patients with glioblastoma multiforme (GBM) are often given glucocorticoids (GCs) to reduce edema. Stress, which produces high levels of endogenous GCs, has been linked to poor prognosis in cancer patients. In this study, therefore, the authors asked whether GC treatment might directly affect GBM cells. The answer was yes: it resulted in cells with a phenotype that resembled glioma stem cells (GSCs) and resistant to chemotherapy. These findings suggest that treatment of GBM with GCs could actually be harmful, contributing to the poor prognosis of the disease and to tumor recurrence via aggressive GSCs.
dexamethasone. The confluent cell monolayer was scratched, leaving a gap depleted of cells. Bright-field images of the gap were obtained immediately and 1 and 2 days later, when cells had migrated into the gap. The images were analyzed with Photoshop CS6 extended version (Adobe). The scratched area was selected with the magnetic lasso tool and the pixel area (corresponding to the area depleted of cells) was measured with the record measurement tool. The percentage area covered with cells over time was calculated as: (1 -pixel area of area at time t/pixel area at time 0) 3 100.
Formation of neurospheres
GBM cells were dissociated into a single cell suspension using TripleSelect (Gibco), washed with PBS, then suspended in stem cell medium containing or not GCs, and cultured in tissue culture plates. One of the following GCs was used at either 10 27 or 10 26 M: dexamethasone, betamethasone, methylprednisolone (Sigma-Aldrich). To determine if GCdriven changes were mediated through the GC receptor, cells were co-treated with 10 25 M of the GC receptor blocker mifepristone (Sigma-Aldrich) and dexamethasone. Fresh medium (containing GC or/and mifepristone) was added to the cells every 3 to 4 days until day 10. For longer-term experiments, no additional fresh medium was added, and the growth of spheres was monitored by light microscopy. When plated at low densities, 1 to 1000 cells were suspended in 100 ll of stem cell medium (in the presence or absence of dexamethasone) and added to 1 well of a 96-well plate (at least 12 replicate wells were utilized). The presence of neurospheres in each well was visually assessed by light microscopy.
Microscopic imaging of cell cultures
Neurospheres were fixed with formaldehyde, incubated with DAPI and Alexa Fluor 488 phalloidin (Thermo Fisher Scientific), and imaged with a Zeiss LSM 700 confocal microscope and Zen 2012 software (Carl Zeiss).
For assessment of cell viability and death within spheres, spheres were washed with PBS, incubated at 378C with Calcein AM (2 lM) and Ethidium homodimer (4 lM) in PBS for 30 min (LIVE/DEAD Viability/Cytotoxicity kit, Invitrogen), then imaged by confocal microscopy. As only cells toward the surface of the spheres could be imaged using this method, spheres were also dissociated into a single cell suspension and incubated with Calcein AM (2 lM) and Ethidium homodimer (4 lM).
Quantitative PCR
Cells were cultured in the presence or absence of dexamethasone. Cellular RNA was isolated with the RNeasy Mini kit (Qiagen) and reverse transcribed to cDNA with the SuperScript III First-Strand kit (Invitrogen, Life Technologies). Taqman PCR and commercially available, predesigned, genespecific gene expression assays (Thermo Fisher Scientific) were used to assess the expression of human genes. The threshold cycle values for each gene were normalized to the expression of the housekeeping gene beta-2-microglobulin. The results are presented as fold increases with respect to control cells not exposed to dexamethasone.
Treatment with lomustine
GBM cells were cultured in the presence or absence of dexamethasone for 2 weeks, and lomustine (8 lg/ml) was added to the culture medium. One, 3 and 7 days later, cell viability was measured with the CellTiter 96 AQueous NonRadioactive Cell Proliferation Assay.
Patient cohort
Patients diagnosed with GBM between December 2012 and 2015 (consecutive cohort) at the Karolinska University Hospital (Stockholm, Sweden) were included. To adjust for differences in known prognostic factors concerning baseline and treatment characteristics, [15] [16] [17] [18] only patients with focal disease, gross total resection (no residual contrast-enhancing tumor based on imaging 24 hrs post-operation), concomitant radiotherapy and chemotherapy 1 (or chemotherapy only for patients > 70 years old), overall curative intention, Karnofsky Performance Status (KPS) of at least 70, and known MGMT methylation status 19 were included. Patients with IDH1 mutation were excluded. The study was approved by the Ethics Committee at the Karolinska Institutet, Stockholm, Sweden (no. 03-220, 2008/628-312). Patient characteristics are listed in Table 1 . Patients were treated with the synthetic GC betamethasone. Tumor recurrence was assessed every 3 months with magnetic resonance imaging. Recurrence was defined according to RANO (response assessment in neurooncology) criteria. 20 
Statistical analysis
For pairwise comparisons, two-tailed t tests were done with Microsoft Excel 2011. For analysis of PFS as a function of GC cumulative dose of duration of GC treatment, KaplanMeier curves were generated with GraphPad Prism 6 (GraphPad Software). Longrank tests for trend and Gehan-BreslowWilcoxon tests were done with GraphPad Prism 6.
Results
GCs induce phenotypic, proliferative and migratory changes in primary GBM cells
Primary GBM cell cultures were established from surgical tumor specimens of three GBM patients (GBM30, GBM42 and GBM48) and cultured in differentiation medium containing 10 27 or 10 26 M of dexamethasone; controls were cultured in medium without dexamethasone. Dexamethasonetreated cells adopted a more elongated, organized and flat shape, which was clearly recognizable within 3 days of culture (Fig. 1a) . Dexamethasone slightly decreased the growth rate of the cells (Fig. 1b) and hampered their ability to migrate in two of the three cultures (Figs. 1c and 1d ).
To identify activated pathways driving this phenotypic change, we used Taqman PCR to quantify changes in the transcription profile of genes involved in stemness, angiogenesis and inflammation after exposure to dexamethasone (Fig. 1, Supporting Information Fig. S1 ). To complement this transcriptional analysis, we quantified the concentration of related cytokines and grow factors secreted by cells over time (Supporting Information Fig. S2a) .
Dexamethasone altered the expression of most of the genes analyzed in each primary cell line (Supporting Information Fig. S1 ). CD133, the most commonly recognized marker of GSCs, was upregulated in GBM30 and GBM48 cells (Fig. 1e) . BMP6 was upregulated in all three cell cultures, but BMP4 secretion was decreased in GBM30 and GBM48 (Supporting Information Fig. S1 ). The stem cellrelated genes SOX2, nestin and notch1 were downregulated (Supporting Information Fig. S1 ). However, dexamethasone did not appear to induce differentiation toward a neural or glial phenotype, as GFAP was downregulated in GBM30 cells and TUBB3 was downregulated in GBM42 cells. Dexamethasone also led to reprogramming away from an osteogenic phenotype, as judged from the substantial downregulation of BGALP. The GC receptor NR3C1 was downregulated in GBM42 ad GBM48 but not in GBM30. As expected from its anti-inflammatory activity, dexamethasone downregulated IL-6 in 2 of the three cultures tested (IL-6 secretion increased in GBM48), but increased secretion of IL-8 in GBM42. Dexamethasone did not significantly affect the expression of angiogenic factors or hTERT.
These results revealed a distinct response to GCs in different tumors, but pointed toward a potentially induced stemness in GBM cells.
GCs induce a stem cell-like phenotype in primary GBM cells
We cultured primary GBM cells in stem cell culture medium (typically used to grow glioma stem cells as non-adherent neurospheres). To facilitate adherence, we coated the plates with laminin, which has been shown to support the culture of GSC. 21, 22 Cells developed a morphology similar to that of cells cultured in differentiation medium (Fig. 2a) . Dexamethasone did not affect the proliferation rate of GBM30 and GBM42 cells, but enhanced the proliferation of GBM48 cells Cancer Therapy and Prevention (Fig. 2b) . Also, dexamethasone appeared to enhance migration when cultured with stem cell medium in the presence of laminin (Supporting Information Fig. S3) .
We compared the gene expression profile and secretory activity of cells cultured under these conditions for 14 days to that of cells cultured in differentiation medium (Supporting Information Figs. S2b and S4) . Culture in stem cell medium markedly enhanced GC-mediated overexpression of CD133, decreased BMP4 secretion, and significantly altered the expression of other genes related to cellular differentiation and de-differentiation. In cells cultured in stem cell medium, dexamethasone upregulated the GC receptor, the angiogenic factor FGF2, the telomerase gene TERT, and the glial marker GFAP.
In the absence of laminin, cells exposed to dexamethasone rapidly expanded their growth as nonadherent neurospheres (Fig. 2c) , which was visible within the first week of culture. We observed a similar effect when using GCs other than dexamethasone, namely betamethasone and methylprednisolone (Supporting Information Fig. S5a ). Moreover, growth as neurospheres was inhibited by the GC receptor blocker mifepristone (Supporting Information Fig. S5 ). The neurospheres had a clear multicellular structure, multiple nuclei and actin filaments within the spheres as shown by confocal microscopy (Fig. 2d) . In addition, we observed that cells within spheres were viable for the most part after a 2-week culture (Supporting Information Fig. S5b) .
To quantify the ability of individual GBM cells to give rise to neurospheres after dexamethasone exposure, we cultured 1, 10, 100 or 1000 cells per well in 96-well plates in stem cell medium containing 10 27 or 10 26 M dexamethasone. Three weeks later, the number of wells with visible spheres was substantially higher in the presence of dexamethasone in all GBM cultures, especially GBM30 cells. After plating as few as 10 cells per well, 8-16% of GBM30 wells exposed to dexamethasone contained neurospheres. When 100 cells were plated, 83% of wells with 10 27 M dexamethasone and 100% of the wells with 10 26 M dexamethasone contained neurospheres. When 1000 cells were plated, all wells exposed to dexamethasone contained neurospheres (Fig. 2e) . Cells not exposed to dexamethasone gave rise to significantly smaller neurospheres (Figs. 2f and 2g ).
Exposure to GCs enhances resistance to chemotherapy and cellular stress
We cultured GBM cells in stem cell or differentiation cell culture medium containing 10 27 or 10 26 M dexamethasone. The medium was changed every 3-4 days until Day 10, after which cells were cultured for 5 to 8 weeks without feeding. Neurospheres formed in the presence of dexamethasone continued to grow in stem cell medium for 45-58 days (Fig. 3a) . We observed a similar response when we treated GBM cells with other GCs, such as betamethasone or methylprednisolone (Fig. 3b) . In the absence of GCs, only small clusters of adherent cells formed. Of importance, cell viability within the spheres was high, ranging between 80 and 95% after 28 days in culture. The core of the spheres appeared densely packed with cells, as only cells on the surface were readily visible by confocal microscopy after incubation with Calcein-AM and ethidium homodimer (Fig. 2c) . However, dissociation of the spheres through enzymatic digestion exposed cells residing within the core (Fig. 2c) . In addition, we verified that formation of neurospheres was mediated through binding of GCs to the GC receptor, as treatment of GBM cells with the GC receptor blocker mifepristone during treatment with dexamethasone dramatically decreased sphere formation (Fig. 3b) . In differentiation medium, the number of cells that remained attached to the surface of the plate was visibly higher when cells were cultured in the presence of dexamethasone (Fig. 3d) . Dexamethasone appeared to confer resistance to nutrient depletion-induced stress. Next, we evaluated the extent to which treatment with dexamethasone could confer cells resistance to chemotherapy. After culturing GBM cells in the presence or absence of dexamethasone, we exposed the cells to the chemotherapy drug lomustine. Treatment with dexamethasone conferred GBM cells resistance to this compound (Fig. 3e) .
Effect of GCs on tumor recurrence in GBM patients
We recorded the cumulative dose of GCs and duration of treatment with GCs from the time of disease onset until tumor recurrence in a cohort of consecutive GBM patients treated at the Karolinska University Hospital (Fig. 4a) . We stratified the patients into 3 groups by the first quartile and median cumulative dose (cutoffs 145.5 and 254.5 mg) or duration (cutoffs 16.75 and 32.5 days) of GC treatment. We found a significant negative correlation between progression-free survival (PFS) and cumulative dose or duration of GC treatment (Figs. 4b  and 4c ). We then divided our patients in two groups based on their MGMT methylation status, as MGMT methylation is associated with longer patient survival. 19 In our cohort, PFS in patients with methylated and unmethylated MGMT was 9 and 5 months, respectively. We further stratified these patients by the median cumulative dose or duration of GC treatment. We observed a negative correlation between PFS and cumulative dose or duration of GC treatment, regardless of the MGMT methylation status (Figs. 4d-4g ).
Discussion
This study shows that exposure of GBM cells to GCs conferred resistance to both chemotherapy and nutrient deprivation, promoted a GSC-like phenotype as judged from the increased expression of CD133, and supported neurosphere formation. Given the vast cellular heterogeneity among GBMs and even within a single GBM 23 and the ubiquitous expression of GC receptors, 7 the dexamethasone-induced differences in gene expression profiles among primary GBM cultures were not surprising. Strikingly, however, GCs strongly regulated genes related to the differentiation status of GBM cells and, despite differences in gene expression profiles, induced consistent Cancer Therapy and Prevention phenotypic changes and consistent resistance to therapy in the three primary GBM cell cultures we tested.
The GC-driven changes in phenotype strongly depended on the cell culture conditions. In differentiation medium or in stem cell medium on laminin-coated plates, both of which facilitate adherence to the culture plate, dexamethasone led to growth in organized patterns of elongated cells with a defined orientation. This structure was reminiscent of healthy tissue generated during well-controlled cellular differentiation and differed radically from the unorganized cellular arrangement in tumors. This observation is consistent with previous research showing that GCs can modulate cell fate and induce differentiation of mesenchymal stem cells into osteogenic, adipogenic and chondrogenic lineages. [24] [25] [26] For example, dexamethasone induces Runx2 expression through FHL2/bcatenin-mediated transcriptional activation, thereby driving osteogenic differentiation in vitro. 27 However, dexamethasone decreased the proliferative and migratory capacity of cells only in differentiation medium. In laminin-coated plates containing stem cell medium, dexamethasone increased the migratory ability of cells. Under nonadherent conditions with stem cell medium, cells grew as neurospheres, even when plated at very low numbers, only in the presence of dexamethasone. Moreover, the gene expression profile varied considerably depending on the culture conditions. These findings highlight the effects of GC-induced modification of the tumor microenvironment on the development and outcome of cancer.
The tumor microenvironment, created through cell-cell contacts, the extracellular matrix, and secretion of factors from neighboring cells, is highly heterogeneous. 28 Therefore, specific niches within a tumor may support the maintenance of cancer stem cells. 29 We found that within a niche that supports cell differentiation, GCs are likely to render GBM cells less proliferative and invasive. Conversely, within a cancer stem cell niche, GCs are likely to render GBM cells more invasive and to support the clonal growth of GSCs that detach from the bulk of the tumor. Regardless of the cell culture medium utilized, GCs conferred resistance to stress from nutrient depletion or chemotherapy on a subpopulation of GBM cells.
These findings suggest that our primary GBM cultures contained two populations: (i) bulk cancer cells that preferentially grow in differentiation medium and become less aggressive when treated with dexamethasone and (ii) GSCs that preferentially grow as neurospheres in dexamethasonecontaining stem cell medium. This scenario is consistent with a hierarchical model of cancer stem cells, in which resident GSCs within a tumor give rise to more differentiated bulk cancer cells. 29 Alternatively, since neurospheres failed to grow in the absence of GCs, GC-containing stem cell medium induced de-differentiation of GBM cells into GSCs. This scenario is consistent with the concept of cancer cell plasticity, in which cancer cells cycle between a more differentiated state and a more stem-like state. 29 In support of this hypothesis, removal of dexamethasone at least partially reversed the growth pattern and gene expression profile from a more stem cell-like phenotype to a more differentiated phenotype (Supporting Information Fig. S6) .
Previous experimental studies have reported conflicting findings on the effect of GCs on cancer cells, which appears to depend on the GC dose, the confluency of cells, and the specific cell line used. [30] [31] [32] Concerns have been raised that GCs may induce proliferation of glioma and other cancer cells. 30, 32 or increase resistance to radiotherapy or chemotherapy. [33] [34] [35] Here, we provide evidence that GCs favor the maintenance and growth of a subpopulation of cells with a GSC-like phenotype, which in part may explain the variable results obtained by different investigators. In a clinical setting, it is complicated to discern the direct effects of GCs on cancer cells, as GCs are often included in multi-therapy regimens and have a potent anti-inflammatory activity that likely reduces the perceived tumor mass. However, a review of the effect of GCs on nonhematologic malignancies concluded that continuous high doses of GCs can have a deleterious effect on patient survival. 36 Also, treatment with GCs could be considered a confounding factor because patients with signs of more aggressive disease and shorter expected survival time typically undergo more aggressive GC regimens. In an effort to adjust for this when analyzing the effect of GC on tumor recurrence in GBM patients, we adjusted our cohort to only include patients with the best prognosis based on predefined criteria: patients with focal disease, gross total resection, overall curative intention of treatment, and a Karnofsky Performance Status (KPS) between 70 and 100. Within this homogenous cohort, we found a significant positive correlation between tumor recurrence and duration or cumulative dose of GC treatment. This finding applied equally to patients with MGMT methylated or unmethylated status. An aggressive GC regimen might shorten the life span of patients by expanding the GSC pool, which is more resistant to low nutrient supply and to chemotherapy. Since the survival time for GBM patients is appallingly short, this possibility warrants in-depth investigation in a clinical setting. Since long-term exposure to GCs has adverse side effects, including hyperglycemia, osteoporosis and myopathy, 8, 37 alternative treatments to reduce the dependency on GCs are already under consideration. For example, anti-angiogenic drugs such as the anti-VEGF monoclonal antibody bevacizumab, which aims to reduce the aberrant and hyperpermeable vasculature of tumors, can be used to reduce brain-associated edema. 10, 38 The possible effects of such therapies on GSCs should be carefully evaluated. In summary, extensive research efforts combining state-ofthe-art technology and the latest understanding of cancer at physiological, cellular and molecular levels have failed to provide a new therapeutic option for GBM patients for the last several decades. Our findings emphasize the need to scrutinize the largely disregarded and potentially deleterious effect that GCs may have on the aggressiveness and recurrence of GBMs, possibly through the maintenance of the GSC population and the reprogramming of GBM cells into GSCs. Our findings also support the notion that treatment of GBM with GCs may contribute to resistance to chemotherapy, tumor recurrence and the poor prognosis of patients.
